1
|
Rayat Pisheh H, Nojabaei FS, Darvishi A, Rayat Pisheh A, Sani M. Cardiac tissue engineering: an emerging approach to the treatment of heart failure. Front Bioeng Biotechnol 2024; 12:1441933. [PMID: 39211011 PMCID: PMC11357970 DOI: 10.3389/fbioe.2024.1441933] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2024] [Accepted: 08/01/2024] [Indexed: 09/04/2024] Open
Abstract
Heart failure is a major health problem in which the heart is unable to pump enough blood to meet the body's needs. It is a progressive disease that becomes more severe over time and can be caused by a variety of factors, including heart attack, cardiomyopathy and heart valve disease. There are various methods to cure this disease, which has many complications and risks. The advancement of knowledge and technology has proposed new methods for many diseases. One of the promising new treatments for heart failure is tissue engineering. Tissue engineering is a field of research that aims to create living tissues and organs to replace damaged or diseased tissue. The goal of tissue engineering in heart failure is to improve cardiac function and reduce the need for heart transplantation. This can be done using the three important principles of cells, biomaterials and signals to improve function or replace heart tissue. The techniques for using cells and biomaterials such as electrospinning, hydrogel synthesis, decellularization, etc. are diverse. Treating heart failure through tissue engineering is still under development and research, but it is hoped that there will be no transplants or invasive surgeries in the near future. In this study, based on the most important research in recent years, we will examine the power of tissue engineering in the treatment of heart failure.
Collapse
Affiliation(s)
- Hossein Rayat Pisheh
- Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran
- Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Fatemeh Sadat Nojabaei
- Department of Medical Biotechnology, Faculty of Allied Medicine, Iran University of Medical Science, Tehran, Iran
| | - Ahmad Darvishi
- School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Ali Rayat Pisheh
- Department of Biology, Payam Noor University (PUN), Shiraz, Iran
| | - Mahsa Sani
- Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran
- Shiraz Institute for Stem Cell & Regenerative Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
| |
Collapse
|
2
|
Hegeman RRMJJ, McManus S, Tóth A, Ladeiras-Lopes R, Kitslaar P, Bui V, Dukker K, Harb SC, Swaans MJ, Ben-Yehuda O, Klein P, Puri R. Reference Values for Inward Displacement in the Normal Left Ventricle: A Novel Method of Regional Left Ventricular Function Assessment. J Cardiovasc Dev Dis 2023; 10:474. [PMID: 38132642 PMCID: PMC10744219 DOI: 10.3390/jcdd10120474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2023] [Revised: 11/11/2023] [Accepted: 11/16/2023] [Indexed: 12/23/2023] Open
Abstract
BACKGROUND Regional functional left ventricular (LV) assessment using current imaging techniques remains limited. Inward displacement (InD) has been developed as a novel technique to assess regional LV function via measurement of the regional displacement of the LV endocardial border across each of the 17 LV segments. Currently, normal ranges for InD are not available for clinical use. The aim of this study was to validate the normal reference limits of InD in healthy adults across all LV segments. METHODS InD was analyzed in 120 healthy subjects with a normal LV ejection fraction, using the three standard long-axis views obtained during cardiac MRI that quantified the degree of inward endocardial wall motion towards the true LV center of contraction. For all LV segments, InD was measured in mm and expressed as a percentage of the theoretical degree of maximal segment contraction towards the true LV centerline. The arithmetic average InD was obtained for each of the 17 segments. The LV was divided into three regions, obtaining average InD at the LV base (segments 1-6), mid-cavity (segments 7-12) and apex (segments 13-17). RESULTS Average InD was 33.4 ± 4.3%. InD was higher in basal and mid-cavity LV segments (32.8 ± 4.1% and 38.1 ± 5.8%) compared to apical LV segments (28.6 ± 7.7%). Interobserver variability correlations for InD were strong (R = 0.80, p < 0.0001). CONCLUSIONS We provide clinically meaningful reference ranges for InD in subjects with normal LV function, which will emerge as an important screening and assessment imaging tool for a range of HFrEF therapies.
Collapse
Affiliation(s)
- Romy R. M. J. J. Hegeman
- Department of Cardiothoracic Surgery, Sint Antonius Hospital, 3435 CM Nieuwegein, The Netherlands
- Department of Cardiothoracic Surgery, Amsterdam University Medical Center, 1105 AZ Amsterdam, The Netherlands
| | | | - Attila Tóth
- Department of Radiology, Gottsegen György Hungarian Institute of Cardiology & Semmelweis University, 1096 Budapest, Hungary
| | - Ricardo Ladeiras-Lopes
- Department of Cardiology, Gaia/Espinho Hospital Centre, Rua Conceicao Fernandes, 4434-502 Vila Nova de Gaia, Portugal
| | - Pieter Kitslaar
- Medis Medical Imaging Systems, 2316 XG Leiden, The Netherlands
| | - Viet Bui
- Medis Medical Imaging Systems, 2316 XG Leiden, The Netherlands
| | - Kayleigh Dukker
- Medis Medical Imaging Systems, 2316 XG Leiden, The Netherlands
| | - Serge C. Harb
- Department of Cardiovascular Medicine, Heart, Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, OH 44195, USA (R.P.)
| | - Martin J. Swaans
- Department of Cardiology, Sint Antonius Hospital, 3435 CM Nieuwegein, The Netherlands
| | - Ori Ben-Yehuda
- Bioventrix Inc., Mansfield, MA 02048, USA
- Sulpizio Cardiovascular Center, University of California San Diego, La Jolla, CA 92037, USA
| | - Patrick Klein
- Department of Cardiothoracic Surgery, Sint Antonius Hospital, 3435 CM Nieuwegein, The Netherlands
- Department of Cardiothoracic Surgery, Amsterdam University Medical Center, 1105 AZ Amsterdam, The Netherlands
| | - Rishi Puri
- Department of Cardiovascular Medicine, Heart, Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, OH 44195, USA (R.P.)
| |
Collapse
|